DarshanTalks Podcast

Send us Fan Mail

In a significant update on September 19th, Samuel Levine, Director of the #FTC's Bureau of Consumer Protection, outlined the agency's key priorities at the National Advertising Division's annual conference. Levine emphasized a three-pillar enforcement agenda. 
The first pillar targets practices causing substantial consumer harm, 
While the second aims not only to cease violative conduct but also alter incentives to deter future misconduct and 
The third pillar introduces tools beyond case-by-case enforcement, emphasizing corrective and preventative actions (CAPA). 
Levine's increased focus on substantive concerns and his expressed concern about "dark patterns" highlight a proactive stance in FTC enforcement. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

This week, a data breach was disclosed by 23andMe, affecting 6.9 million users and compromising their genetic data information.

The incident raises significant concerns about data privacy and security. It's important to note that while some perceive this as a violation of HIPAA, it typically doesn't apply to direct-to-consumer genetic testing services like 23andMe, as they don't involve covered entities such as physicians. This leaves a gap in privacy protection, and alternative legal frameworks, such as those enforced by the Federal Trade Commission, may come into play. However, actions against direct-to-consumer genetic testing companies by the FTC have been rare. The breach highlights the need for increased awareness and potentially new laws and regulations to safeguard sensitive genetic data in the rapidly evolving digital landscape.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Guest Istvan Fekete discusses what large academic medical institutions are responsible for that sponsors and other commercial entities are generally not. Key considerations include the complexities of handling publication rights, the impact of tax-exempt municipal bonds on project restrictions, ensuring equal patient treatment, the reality of universities generating revenue from intellectual property, the distinct goals of principal investigators versus institutions, and the necessity of a comprehensive congruence review among documents related to clinical trial agreements.
 
Points discussed:

1. What are the 6 big areas that large academic medical institutions tend to think about that sponsors or smaller hospitals/private institutions may not be thinking about in the context of clinical trial negotiations? - 2:29- 4:55
2. Are tax-exempt municipal bonds a factor in clinical trial negotiations? 4:58- 12:03
3. What is the impact of the Bayh-Dole Act on publication rights? 12: 04- 13:40
4. Why do we not discuss confidentiality as much as we talk about publication rights?- 13:41- 21:26
5.  Should sponsors have the right to be present during an FDA audit in a large medical center?- 21:27- 24:19
6. Should sponsors have a right to review and change a proposed audit in the case of a larger academic medical center? Check out our latest podcast episode to find out. 24:20- 26:20
7. 6 different types of clinical trial transparency. - 26:21- 29:30 

Disclaimers:
This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice or medical advice. Listening to this video or otherwise depending on discussions in this video do not, in any way, create an attorney attorney-client relationship.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this video,, the focus is on the growing interest in digital engagement programs among FDA-regulated companies, but it also addresses the concerns raised by regulatory agencies such as the FDA, DOJ, FTC, and OIG. The discussion revolves around the risk-based review of outward-facing information shared by medical device companies. The podcast delves into seven hierarchical layers that dictate how organizations should approach compliance. These layers include:

1. The Constitution (First Amendment): Highlighting the clash between First Amendment rights like free speech and FDA regulations. Emphasizes the importance of truthful and non-misleading information.

2. Laws Made by Congress: Discussing how laws such as the Food, Drugs, and Cosmetics Act set the rules but can be ambiguous, potentially leading to regulatory challenges.

3. Regulatory Agency Interpretation: Exploring how FDA, FTC, and OIG interpretations through regulations, guidances, and enforcement actions add another layer of compliance focus for Pharma companies.

4. CIA Settlements: Examining Integrity Agreements or CIA settlements as legal precedents that set industry wide regulatory expectations for Pharma companies.

5. Industry Codes: Discussing voluntary codes like Pharma or AdvaMed codes, which, while not legally binding, may influence industry standards.

6. Internal Policies: Highlighting the importance of company-set policies for day-to-day operations, which are more conservative than the law but serve as prudent forms of engagement.

7. Personal Risk Tolerance: Acknowledging that individual risk tolerance varies, and while policies guide the process, they won't eliminate personal risk tolerance.

The podcast emphasizes the need for companies to navigate these layers carefully and stay informed and compliant. It concludes with an invitation to seek assistance in creating digital health engagement programs by contacting the speaker via email at [email protected]

Website: http://www.darshantalks.com
Law Firm: http://www.kulkarnilawfirm.com
Twitter: https://twitter.com/darshantalks
LinkedIn: https://www.linkedin.com/in/darshanku...

----
Disclaimers:
This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice or medical advice. Listening to this video or otherwise depending on discussions in this video do not, in any way, create an attorney attorney-client relationship

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni talks about how the generic drug industry is facing several challenges that are impacting profitability, including:

1. Pressure from insurers to lower prices,
2. Rising costs of manufacturing and distribution,
3. Inflation,
4. Supply chain disruptions and
5. Increased competition from other generic companies

Pharmacies are fighting back against these challenges by:

1. Bypassing wholesalers and negotiating directly with manufacturers,
2. Offering discounts and coupons to patients and
3. Partnering with other organizations to negotiate lower prices

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Recently, Celia Sandhya Daniels was announced to be one of the top 20 LGBTQ leaders in Bio Pharma by Endpoints News.

In this episode, We're venturing into the captivating world of Diversity, Equity, and Inclusion (DEI) in the realm of pharmaceuticals and healthcare. Get ready for a journey that will unravel the mysteries and intricacies of DEI!

We’re joined by Celia Sunday Daniels, a seasoned professional with 25 years of experience in the pharmaceutical and healthcare industry.

We discuss:

Why is DEI crucial, especially in a world where companies could face scrutiny for advocating DEI? (3:07- 9:13)
How can we reconcile the goals of DEI with privacy concerns? (10:20- 18:32)
Does the FDA prioritize certain intersections more than others in its risk-based approach to DEI? (18:44- 24:33) 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The case study on academic research center misconduct highlights the urgency to address and prevent such issues in the field. Instances of research misconduct, as exemplified by the Miami case, have drawn the attention of regulatory agencies like the Department of Justice, emphasizing the need for stringent oversight and ethical conduct. Examining the fictional case of Padre Pio Hospital in Philadelphia reveals the complexities and challenges involved in managing research misconduct, requiring strict adherence to FDA and IRB guidelines, staff training, and internal auditing. 
To effectively address the situation, a comprehensive compliance program, self-disclosure, and corrective actions as per the FDA, OIG, and DOJ guidelines must be implemented, underscoring the importance of ethical conduct, timely reporting, and ongoing staff training in research centers.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Planning to incorporate artificial intelligence into your business in 2024? Stay informed about the Federal Trade Commission's (FTC) expectations. In his discussion, Darshan Kulkarni highlights the FTC's recommendations for AI:
FTC expects that AI will foster fair, open and competitive markets,
FTC intends to use its tools to challenge unfair and deceptive practices involving claims based on AI including the use of AI to discriminate the and 
FTC intends to promulgate market-wide rules to address harms from AI this includes fake reviews impersonators and other issues.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Jessica Thompson discusses how project management can be a game-changer in clinical research.  We talk about how poor project management can lead to delays, cost overruns, and regulatory violations, and that lawyers can play a role in ensuring that clinical research projects are managed effectively. Thompson emphasized the need for early planning and communication between all stakeholders involved in a clinical research project.

Points discussed:

Do clinical research project management tools differ from those used in other industries?-  1:58- 4:25

What does the term 'critical path' mean?- 4:25- 6:34

How to companies respond to the concept of critical path?- 6:53- 8:46

How is Association of Clinical Research Professionals (ACRP) connected to Association of Clinical Research Project Managers (ACRPM)?- 9:54- 12:01

How should sponsors involve project managers in their projects?- 12:04- 18:47

Is a project manager different from a manager?- 19:07- 21:00

How do Kaizen and Lean Six Sigma fir into clinical research project management?- 21:02- 22:47

What is the significance of the Iron Triangle in clinical research project management?- 22:49- 28:08

What is the advantage of being a part of ACRPM?- 28:34- 30:48
 
Sign up for our newsletter- https://darshantalks.com/ 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Virginia Tech recently received a $50 million gift from the Red Gates Foundation for Health Sciences research expansion. In light of recent news about research fraud prosecuted by the Department of Justice, it is crucial for the Fralin Biomedical Research Institute to implement robust research integrity policies.
Here are five key steps that the institute can take to address research fraud:
1.  develop and implement a clear research integrity policy,
2.  establish written procedures,
3.  provide comprehensive training on research integrity,
4.  form a research integrity committee, and
5.  encourage the reporting of suspected misconduct.

Support the show

www.kulkarnilawfirm.com